SI-BONE
SI-BONE's revenue rose 20.2% to $201 million in fiscal 2025. Its operating margin was −11.1%, up from −21.1% a year earlier. Free cash flow was −$9 million. The diluted share count rose 3.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What SI-BONE does
SI-BONE makes medical implants for the pelvis and spine. Its first product, iFuse, is a titanium implant that stabilizes and fuses the sacroiliac joint, where the spine meets the pelvis, to treat pain from dysfunction or degeneration of that joint. The company describes itself as a pioneer of minimally invasive treatment for this condition.
It sells a series of patented titanium implants, the tools used to place them, and implantable bone products. Newer lines, such as iFuse 3D, iFuse TORQ and iFuse Bedrock Granite, are 3D-printed and extend the products to adult spinal deformity and pelvic trauma. Hospitals and surgeons are its customers. It sells mainly through its own sales force and third-party sales agents in the United States, and through its own staff, agents and resellers in other countries.
The company depends heavily on sales of products for sacroiliac joint procedures. It says it competes in a very competitive business and that procedures are shifting from hospitals to ambulatory surgical centers. Its products need US FDA clearance or European CE marking in each market.
Its biggest risks, as it describes them
- Competing in a very competitive market, with pressure on its prices.
- Operating losses since it began, with no assurance it will reach profitability.
- Hospitals and doctors may not get adequate insurer coverage and payment for procedures using its products.
- Reliance on sacroiliac joint products, which have been most of its sales.
- Depending on a few suppliers, some with a single source or single location.
Income statement
SI-BONE lost money in fiscal 2025: a net loss of $19 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 147 | 85 | 156 | 142 | 139 |
| Debt incl. finance leases | 35 | 35 | 36 | 36 | 36 |
| Net debt (negative means net cash) | −112 | −49 | −120 | −107 | −104 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.3x | 0.4x | 0.2x | 0.2x | 0.2x |
| Interest coverage | −9.6x | −21.1x | −13.6x | −10.2x | −8.5x |
| Current ratio | 10.4x | 6.5x | 9.0x | 7.7x | 8.6x |
| Quick ratio | 9.7x | 5.7x | 8.2x | 6.7x | 7.2x |
Cash flow
Projections
Project SI-BONE's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of SI-BONE reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 4 of 9 | 6 of 9 |
| Rule of 40 | 11.4% | 6.7% | 15.7% |
| Altman Z'' | 1.23 | 0.77 | 1.52 |
| Accruals ratio | −12.7% | −8.0% | −7.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 5 of 9 | 4 of 9 | 6 of 9 |
Compare
Put SI-BONE side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| SI-BONE | FY25 | 20.2% | −11.1% | −4.5% | −26.3% | — | 6 | |
| Establishment Labs Holdings | FY25 | 27.1% | −18.5% | −27.0% | −39.0% | — | 3 | Compare |
| Axogen | FY25 | 20.2% | −3.5% | −1.3% | −4.9% | — | 5 | Compare |
| Cerus | FY25 | 16.1% | −3.7% | 0.5% | — | — | — | Compare |
| Orthopediatrics | FY25 | 15.4% | −16.6% | −6.8% | −8.2% | — | 4 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 48 | 55 | 67 | 73 | 90 | 106 | 139 | 167 | 201 |
| Revenue growth | — | 15.4% | 21.5% | 9.0% | 22.8% | 18.0% | 30.5% | 20.4% | 20.2% |
| Gross profit | 43 | 50 | 60 | 64 | 80 | 91 | 109 | 132 | 160 |
| Research and development | 6 | 5 | 7 | 10 | 12 | 14 | 15 | 17 | 17 |
| Operating income | −17 | −12 | −36 | −39 | −52 | −60 | −47 | −35 | −22 |
| Net income | −23 | −18 | −38 | −44 | −57 | −61 | −43 | −31 | −19 |
| Diluted EPS (US$) | −6.65 | −2.20 | −1.55 | −1.50 | −1.71 | −1.79 | −1.13 | −0.75 | −0.44 |
| Diluted shares (millions) | 4 | 8 | 25 | 29 | 33 | 34 | 38 | 42 | 43 |
| Cash flow | |||||||||
| Cash from operations | −18 | −14 | −32 | −31 | −40 | −42 | −19 | −12 | −1 |
| Capital expenditure | 0 | 1 | 2 | 3 | 6 | 10 | 8 | 10 | 8 |
| Free cash flow | −18 | −15 | −34 | −33 | −46 | −51 | −27 | −23 | −9 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 2 | 8 | 12 | 17 | 23 | 24 | 26 | 26 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 22 | 122 | 93 | 196 | 147 | 85 | 156 | 142 | 139 |
| Debt incl. finance leases | 39 | 39 | 39 | 40 | 35 | 35 | 36 | 36 | 36 |
| Total assets | 36 | 138 | 117 | 223 | 190 | 158 | 230 | 230 | 239 |
| Total liabilities | 47 | 48 | 54 | 54 | 56 | 59 | 61 | 64 | 61 |
| Shareholders' equity | −129 | 90 | 63 | 169 | 134 | 98 | 169 | 167 | 178 |
| Margins and ratios | |||||||||
| Gross margin | 89.3% | 91.3% | 89.9% | 87.9% | 88.4% | 85.2% | 78.8% | 79.0% | 79.6% |
| Operating margin | −36.2% | −21.6% | −53.5% | −52.5% | −57.3% | −56.0% | −33.8% | −21.1% | −11.1% |
| Net margin | −48.0% | −31.5% | −57.1% | −59.5% | −62.8% | −57.6% | −31.2% | −18.5% | −9.4% |
| Free cash flow margin | −37.5% | −27.9% | −50.6% | −45.3% | −50.9% | −48.1% | −19.1% | −13.7% | −4.5% |
| Rule of 40 (growth + FCF margin) | — | −12.5% | −29.1% | −36.2% | −28.1% | −30.1% | 11.4% | 6.7% | 15.7% |
| Return on capital | — | — | — | — | — | −132.1% | −75.5% | −50.9% | −26.3% |
| Return on equity | — | — | −50.1% | −37.6% | −37.2% | −52.6% | −32.4% | −18.4% | −11.0% |
| Return on assets | — | −20.0% | −30.1% | −25.7% | −27.4% | −35.2% | −22.3% | −13.4% | −8.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |